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Pulmonary Vein Angiography and Spike Potential Mapping Guided
Ultrasound Ablation in Pulmonary Vein Ostium to Treat Focal Atrial
Fibrillation
CAIYI LU, CHANGSHENG MA, SHIWEN WANG, YUFENG LI, MUYANG YAN, RUI CHEN, PENG LIU,
ZHONGREN ZHAO
From General Hospital of PLA, Beijing 100853, China
LU ET AL.: Pulmonary Vein Angiography and Spike Potential Mapping Guided Ultrasound Ablation in Pulmonary
Vein Ostium to Treat Focal Atrial Fibrillation. Objectives: The purpose is to evaluate the effect of pulmonary vein
angiography (PVA) and spike potential (PSP) mapping guided ultrasound ablation in the pulmonary vein ostium
(PVO) to treat focal atrial fibrillation (FAf). Methods: The criteria of patient enrollment were: 1) paroxysmal FAf
≥6 months, 2) the FAf was refractory to antiarrhythmic agents, 3) without organic heart disease, 4) frequent P'-on-T
atrial premature beat (APB) and 5) its induced FAf on Holter. R1 and L1 Swartz sheaths were positioned at PVOs by
transseptal approach. PVA was conducted to direct PSP and APB mapping. Target PVO was: 1) clear and stable
PSP, 2) earliest APB orientation, 3) PSP driven or triggered FAf. An ultrasound balloon catheter was inserted to
ablate target PVO with the parameters of temperature ≥60°C and time 60~120s. The end points were 1) PSP
disappeared or its amplitude decreased more than 80%, 2) complete conduction block from PVO to the left atrium,
3) actual ablation temperature ≥50°C and keeping for ≥60s. Results: Total 24 PVOs (9 left and 9 right superior,
6 left inferior) of 9 patients (M/F 8/1, 57.6±8.3 years old) were ablated. Each PVO was ablated 4.3±1.5 times with
actual temperature of 57.2±3.6°C and duration of 96.8±12.5s. The PSP of 8 PVOs (33.3%) disappeared and the
amplitude of others was decreased more than 80%. All patients had chest pain during ablation and seven of them
were injected opium. There were no complications. All patients had FAf recurred within 48.3±11.7 hours after
ablation and previous anti-arrhythmic drugs were then started. During follow-up of 11.8±7.5 month, the frequency
of FAf decreased from 5.7±3.9 times per week before ablation to 2.4±0.7 times per week after ablation in 7 patients
(77.8%, P<0.05). Another two patients had no FAf recurrence (22.2%). Conclusions: 1) The end points of APB and
PSP disappearance, actual temperature ≥50°C cannot predict immediate and long-term ablation effect of focal FAf.
2) Late remodeling effect of ablated PVO may be one factor to reduce FAf attack. 3) The method of PVA and PSP
mapping guided ultrasound ablation in PVO may not be a radical cure to focal FAf. (J HK Coll Cardiol 2003;11:3945)
Focal atrial fibrillation, Interventional therapy
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Focal atrial fibrillation (FAf) is triggered or driven
by abnormal focus orientated from myocardial sleeve
structures such as pulmonary vein or vena cava ostium.
The patients with FAf usually have not organic heart
disease or purely have slight atrial enlargement.1-3 Some
investigating Intervention therapies could be used to
cure the disease by ablating the abnormal focus or
isolating its conduction from the sleeve structure to the
atria.4-6 The purpose of the study is to evaluate the effect
of pulmonary vein angiography (PVA) and spike
potential (PSP) mapping guided ultrasound ablation in
the pulmonary vein ostium (PVO) to treat focal atrial
fibrillation (FAf).

Material and Methods
Clinical Cases
Patients with following characters were enrolled
into the study: 1) more than 6 months of paroxysmal
atrial fibrillation; 2) refractory to prophylactic
antiarrhythmic agents such as amiodarone, propafenone,
verapamil or sotalol; 3) without organic heart disease,
4) frequent P' on T atrial premature beats (APB) on
Holter monitoring (Figure 1A), 5) FAf induced by APB
was recorded on surface electrocardiogram (ECG).

Electrophysiological Study
Informed consent was written before electrophysiological study and ultrasound balloon catheter
ablation. Both procedures were conducted at one time
in catheterization laboratory. Patient was lying on
X-ray bed and slight sedation was given. One
quadrapolar electrode catheter (6F, USCI) was inserted
into coronary sinus through left subclavicular vein. Two
quadrapolar electrode catheters (6F, USCI) were
inserted to record His potential and stimulate right
40
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ventricular apex through right femoral vein. One
steerable A-focus electrode catheter (5F, IBI) was sent
into the interested pulmonary veins by transseptal
approach to record the target APB and map induced or
spontaneous FAf. Pulmonary vein was determined by
retrograde contrast angiography through transseptal
sheath (Figure 1B). Regular programming electrode
stimuli (UHS20, Biotronik) was conducted to exclude
the accessory pathway or other supraventricular
tachycardia. Repeat atrial program or non-program
stimuli were tried to induce FAf. Five thousands unit
common heparin was injected after transseptal Swartz
sheath (8F, L1, Swartz) was in position and another
thousand unit was added in one hour. Fluoroscopy
machine was Digital INNOVA2000 (GE Medical).
The pulmonary vein with more than two items
of the following characters was considered as target
vein: 1) clear and stable pulmonary spike potential (PSP)
could be recorded, 2) PSP was disintegrate or block,
3) earliest APB was recorded, 4) FAf triggered or driven
by the pulmonary APB was recorded.

Ultrasound Balloon Catheter Ablation
A special transseptal sheath was inserted into left
artium by second transseptal access (11F, IBI). It was
further positioned into the target pulmonary vein ostium
under the guidance of a 7F steerable large tip electrode
catheter (Webster/Mansfield).
Through the IBI transseptal sheath, a steerable
ultrasound balloon catheter was inserted into the target
pulmonary vein ostium (10F, IBI). This catheter has
three main functions. Firstly, it could be used as a
steerable mapping and radiofrequency ablation catheter.
Secondly, its tip inflatable balloon could contact tightly
with the vascular inner wall and make precious position
for the ultrasound core mounted in the central staff of
the balloon. Thirdly, when the tip balloon was inflated,
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it stops the blood flush from the lung to the ablated
area so as to ensure the heat ablation efficacy. The
structure of the ultrasound ablation catheter in detail
refers to Figure 2A. The size of the tip balloon could be
adjusted preciously by injected normal saline mixture
with contrast. The temperature of the balloon saline
could be sensed and adjusted preciously by an
ultrasound ablation generator IBI-2000 (Figure 2B).
After the target pulmonary vein was determined,
the diameter of its ostium was measured by
angiography. The ultrasound balloon was then
preciously located at 1 cm inner the ostium and inflated

to the ostium diameter under fluoroscopy and
angiography (Figure 3). Ablation temperature was
preset at 60°C. Actual temperature was continuously
monitored. If patient feel chest pain, a small dose of
morphine agent was injected intravenously. Each
ablation persisted 60~120s. After 2 to 3 times of
ablation, the electrophysiology of the ablated target
pulmonary vein ostium was repeated. Any three of the
following parameters were used to be ablation end point:
1) PSP was disappearance, disintegrate or decreased
80% in its amplitude (Figure 4); 2) PSP or stimulus
was blocked between pulmonary vein and left atrium.

Figure 1. (A) Frequent atrial premature beat of P' on T triggered burst atrial fibrillation on Holter monitoring. (B) Left
superior pulmonary vein was determined by retrograde angiography at 30° right anterior oblique projection through
the transseptal sheath.

Figure 2. Configuration of a ultrasound balloon catheter (A) and an ultrasound ablation generator
(B). They were manufactured by IBI Co. Ltd.
J HK Coll Cardiol, Vol 11
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Figure 3. Ultrasound balloon location under the guidance of target pulmonary vein ostium
angiography. (A) Left superior pulmonary vein ostium ablation under 45° left anterior oblique
projection. (B) Right superior pulmonary vein ostium under 60° left anterior oblique projection.

Figure 4. One of the end points of ultrasound balloon ablation: pulmonary spike potential was
disappearance, disintegrate or decreased 80% in its amplitude. From top to bottom, the
electrocardiograms were surface lead I, II, III, A-focus electrogram 1 to 5 leads, coronary sinus
1-2 leads and ablation catheter electrogram. (A) Spike potential (arrow) of right superior
pulmonary vein ostium was recorded in sinus rhythm before ablation. (B) The spike potential in
A was disappeared after two times of ablation. (C) Spike potential (arrow) of left superior
pulmonary vein ostium was recorded during coronary sinus pacing before ablation. (D) The
spike potential in C was disappeared after three times of ablation.
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3) The earliest APB was cleared away; 4) Monitored
actual ablation temperature was higher than 50°C and
persisted at least 60 seconds; 5) FAf was stopped by
ablation and could not be induced by programmable
stimulus as well as drug provocation.

pulmonary vein angiography was needed because no
patient was suspected of secondary pulmonary vein
stenosis clinically.

Discussion
Follow Up
The patients were followed up clinically in 6
months. FAf frequency and persist time, the effect of
antiarrhythmic agents and chest film were compared
before and after ablation. For patient suspected of
secondary pulmonary vein stenosis clinically, selective
pulmonary vein angiogram was conducted.

Statistics
The material was presented in mean±standard
error. Student t test was used to compare the difference
between two groups and P≤0.05 was considered
significant difference.

Results
Nine patients were enrolled into the study. There
were eight males and one female with mean age of
57.6±8.3 years old. Altogether 24 target pulmonary
veins were determined. They were nine left superior
pulmonary veins, nine right superior pulmonary veins
and six left inferior pulmonary veins. Mean 4.3±1.5
times of ablation were conducted to each target
pulmonary vein ostium. Actual ablation temperature per
delivery was 57.2±3.6°C. The total ablation time per
case was 378.6±41.3s.
The PSPs of eight target pulmonary veins were
completely disappeared (33.3%). The amplitude of other
sixteen target pulmonary veins (66.7%) decreased in
more than 80%. Nine patients felt obvious chest pain
and seven of them needed morphine agent injection.
There were no micro or minor complications.
Nine patients recurred FAf in 48.3±11.7 h after
ablation procedure (100%). During the follow up of
11.8±7.5 months, the frequency of FAf decreased from
5.7±3.9 times per week before ablation to 2.4±0.7 times
per week after ablation in 7 patients (77.8%, P<0.05).
Another two patients had no FAf recurrence (22.2%).
There were no mortality and procedure related
complications. The chest X-ray films were not different
between before and after ablations. No selective
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The Mechanism of Focal Atrial Fibrillation
In clinical, atrial fibrillation could be categorized
into three main types: paroxysmal, persistent and
permanent. The first one is usually developed in
relatively normal heart. Majority FAfs are included into
this category. But the later two are often complicated
with organic heart disease and atrial enlargement. In
electrophysiology, atrial fibrillation is divided into focus
and randomized reentrant according to its mechanism.
Focal atrial fibrillation (FAf) is triggered or driven by
critical atrial premature beats or irregular exciting focus
orientated from some atrial myocardial sleeve
structures. Randomized reentry atrial fibrillation is
dependent on multiple randomized micro-reentry
circuses moving in the atria. 7-12 Common atrial
myocardial sleeve structures are pulmonary vein ostium,
vena cava ostium, coronary sinus ostium and atrial
appendages. Among them, left pulmonary vein ostium
is the most interested area. It is related to more than
85% of clinical FAf cases.7-9,13 Therefore, therapies such
as electrophysiological ablation or isolation to
pulmonary vein are very important theoretically to the
cure of FAf.

The Electrophysiology of Pulmonary Vein
Ostium
In anatomy, there are more or less atrial
myocardium in the conjunction part between left atrium
and pulmonary vein. We usually call this part transition
area or atrial myocardial sleeve. It could be deep into
the pulmonary vein in more than 5 centimeters.7-9,14,15
In normal heart, the myocardium within the sleeve is
excited by impulse orientated from left atrial wall and
produces special pulmonary spike potential (PSP). PSP
is usually a high frequency and low amplitude potential
after atrial wave.7,13,14 When an atrial premature beat or
FAf within the sleeve occurs, PSP transfers to the front
of the atrial wave. By mapping with multiple electrodes
catheter, PSPs in the sleeve have different conduction
type and/or time. So some investigators believe FAf is
in nature an irregular atrial tachycardia.7,14,16
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By programmable stimulus delivered in both
sleeve and left atrium, it is found PSP has decreased
conduction characteristics of slow response fibers. There
is one or more slow conduction parts existed in the
sleeve. Ablating abnormal electrical focus itself or just
blocking the conduction of the key parts within the sleeve
could cure FAf provoked by this mechanism.9-11

Interventional Therapy for FAf
According to the research results on the
mechanism of FAf, the interventional therapies used in
clinic at present are mainly:9-11 1) radiofrequency or
ultrasound energy ablation to the electrical focus and/
or its conduction guided by the guidance of pulmonary
vein angiography and precious electrical mapping to
the sleeve structure (spot ablation); 2) radiofrequency
energy isolation to the sleeve within or outside its ostium
guided by noncontact electroanatomical mapping or
endoscopy (cirlus ablation); 3) dual atrial pacemaker
implantation. These techniques are under investigation
and their effects on FAf are still controversy.7-9

during the interventional procedure, its long-term effect
could not be accurately forecasted; 2) Because the small
case group, selective bias could not be avoided;
3) Pulmonary vein stenosis could not excluded
completely for pulmonary vein angiography is not a
necessary follow up item; 4) Not being a randomized
and controlled trial, the natural variation of FAf and
observer bias may be participated in the long-term
prophylactic effect of the therapy. Therefore, further
investigations are needed to confirm the long-term
efficacy.

Conclusions
1) Atrial premature beat disappearance, PSP
amplitude decrease, and actual ablation temperature
might not be reliable end points during the procedure
of ultrasound balloon catheter ablation to FAf; 2) The
remodeling of the target pulmonary vein ostium may
be one of the factors to the prophylactic effect of the
therapy; 3) The immediate reocurring of FAf after
ultrasound balloon catheter ablation does not completely
represent its long-term effect.

The Effect of Ultrasound Balloon Catheter
Ablation to FAf
When the ultrasound balloon is positioned in the
target pulmonary vein ostium, critical amount of normal
saline mixture with contrast is used to inflate the balloon.
After the ultrasound generator started, the saline within
the balloon is heated. The heat is conducted and makes
injury to the sleeve wall. The ablation course could be
controlled by adjustment to the temperature of saline
and the time of ultrasound energy delivered. 17 The
advantages of this intervention are: 1) simpler
procedure; 2) less dependent to complex electrophysiological study; 3) oven injury to the sleeve wall,
4) minor stenosis of target pulmonary vein. Its
disadvantages include: 1) poor portion selection;
2) more serious injury than spot ablation, 3) poor contact
between the irregular morphology of the sleeve and
regular balloon morphology. In our study, unsatisfied
immediate ablation effect may be due to above
disadvantages of the intervention. The long-term
prophylactic effect would be related to the remodeling
of the ablated sleeve structures.

Limitation of the Study
Followings are the major limitations of the study:
1) Due to the shortage of determined ablation end points
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